ZTS Quote, Financials, Valuation and Earnings

Catalyst Pharmaceuticals, Inc. has a net margin of 30.04% compared to Zoetis, Inc.'s net margin of 35.57%. Zoetis, Inc.'s return on equity of 52.95% beat Catalyst Pharmaceuticals, Inc.'s return on equity of 27.48%.

Zoetis, Inc. has a consensus price target of $165.36, signalling upside risk potential of 37.03%. On the other hand Catalyst Pharmaceuticals, Inc. has an analysts' consensus of $34.86 which suggests that it could grow by 51.03%. Given that Catalyst Pharmaceuticals, Inc. has higher upside potential than Zoetis, Inc., analysts believe Catalyst Pharmaceuticals, Inc. is more attractive than Zoetis, Inc..

Zoetis, Inc. has a beta of 0.972, which suggesting that the stock is 2.841% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals, Inc. has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.5%.

Zoetis, Inc. has a quarterly dividend of $0.50 per share corresponding to a yield of 1.63%. Catalyst Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zoetis, Inc. pays 32.86% of its earnings as a dividend. Catalyst Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. Zoetis, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis, Inc. quarterly revenues are $2.4B, which are larger than Catalyst Pharmaceuticals, Inc. quarterly revenues of $148.4M. Zoetis, Inc.'s net income of $721M is higher than Catalyst Pharmaceuticals, Inc.'s net income of $52.8M. Notably, Zoetis, Inc.'s price-to-earnings ratio is 20.65x while Catalyst Pharmaceuticals, Inc.'s PE ratio is 13.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis, Inc. is 5.83x versus 5.07x for Catalyst Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Elanco Animal Health, Inc. has a net margin of 30.04% compared to Zoetis, Inc.'s net margin of -2.99%. Zoetis, Inc.'s return on equity of 52.95% beat Elanco Animal Health, Inc.'s return on equity of 0.55%.

Zoetis, Inc. has a consensus price target of $165.36, signalling upside risk potential of 37.03%. On the other hand Elanco Animal Health, Inc. has an analysts' consensus of $24.08 which suggests that it could grow by 9.52%. Given that Zoetis, Inc. has higher upside potential than Elanco Animal Health, Inc., analysts believe Zoetis, Inc. is more attractive than Elanco Animal Health, Inc..

Zoetis, Inc. has a beta of 0.972, which suggesting that the stock is 2.841% less volatile than S&P 500. In comparison Elanco Animal Health, Inc. has a beta of 1.859, suggesting its more volatile than the S&P 500 by 85.894%.

Zoetis, Inc. has a quarterly dividend of $0.50 per share corresponding to a yield of 1.63%. Elanco Animal Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zoetis, Inc. pays 32.86% of its earnings as a dividend. Elanco Animal Health, Inc. pays out -- of its earnings as a dividend. Zoetis, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis, Inc. quarterly revenues are $2.4B, which are larger than Elanco Animal Health, Inc. quarterly revenues of $1.1B. Zoetis, Inc.'s net income of $721M is higher than Elanco Animal Health, Inc.'s net income of -$34M. Notably, Zoetis, Inc.'s price-to-earnings ratio is 20.65x while Elanco Animal Health, Inc.'s PE ratio is 301.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis, Inc. is 5.83x versus 2.38x for Elanco Animal Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

IDEXX Laboratories, Inc. has a net margin of 30.04% compared to Zoetis, Inc.'s net margin of 24.85%. Zoetis, Inc.'s return on equity of 52.95% beat IDEXX Laboratories, Inc.'s return on equity of 66.88%.

Zoetis, Inc. has a consensus price target of $165.36, signalling upside risk potential of 37.03%. On the other hand IDEXX Laboratories, Inc. has an analysts' consensus of $759.00 which suggests that it could grow by 4.56%. Given that Zoetis, Inc. has higher upside potential than IDEXX Laboratories, Inc., analysts believe Zoetis, Inc. is more attractive than IDEXX Laboratories, Inc..

Zoetis, Inc. has a beta of 0.972, which suggesting that the stock is 2.841% less volatile than S&P 500. In comparison IDEXX Laboratories, Inc. has a beta of 1.668, suggesting its more volatile than the S&P 500 by 66.77%.

Zoetis, Inc. has a quarterly dividend of $0.50 per share corresponding to a yield of 1.63%. IDEXX Laboratories, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zoetis, Inc. pays 32.86% of its earnings as a dividend. IDEXX Laboratories, Inc. pays out -- of its earnings as a dividend. Zoetis, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis, Inc. quarterly revenues are $2.4B, which are larger than IDEXX Laboratories, Inc. quarterly revenues of $1.1B. Zoetis, Inc.'s net income of $721M is higher than IDEXX Laboratories, Inc.'s net income of $274.6M. Notably, Zoetis, Inc.'s price-to-earnings ratio is 20.65x while IDEXX Laboratories, Inc.'s PE ratio is 57.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis, Inc. is 5.83x versus 14.20x for IDEXX Laboratories, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of 30.04% compared to Zoetis, Inc.'s net margin of 21.32%. Zoetis, Inc.'s return on equity of 52.95% beat Pfizer Inc.'s return on equity of 10.84%.

Zoetis, Inc. has a consensus price target of $165.36, signalling upside risk potential of 37.03%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 13.57%. Given that Zoetis, Inc. has higher upside potential than Pfizer Inc., analysts believe Zoetis, Inc. is more attractive than Pfizer Inc..

Zoetis, Inc. has a beta of 0.972, which suggesting that the stock is 2.841% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Zoetis, Inc. has a quarterly dividend of $0.50 per share corresponding to a yield of 1.63%. Pfizer Inc. offers a yield of 6.73% to investors and pays a quarterly dividend of $0.43 per share. Zoetis, Inc. pays 32.86% of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend. Zoetis, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer Inc.'s is not.

Zoetis, Inc. quarterly revenues are $2.4B, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Zoetis, Inc.'s net income of $721M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Zoetis, Inc.'s price-to-earnings ratio is 20.65x while Pfizer Inc.'s PE ratio is 14.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis, Inc. is 5.83x versus 2.32x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.